MoonLake Immunotherapeutics enters three-year partnership with Komodo Health

MoonLake Immunotherapeutics and Komodo Health announce a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The two companies will collaborate to maximize the impact of MoonLake’s nanobody-based therapy in hidradenitis suppurativa and active psoriatic arthritis, two underdiagnosed diseases with significant unmet patient needs. Through this multiyear technology partnership, MoonLake will utilize Komodo’s Healthcare Map and platform technologies to enable data-driven decision making across its clinical operations, medical, marketing, and market access teams. Tino Anthamatten, VP Marketing & Market Access & Pricing, MoonLake Immunotherapeutics, commented: “We need an experienced technology partner that can help accelerate our disease insights for our clinical, medical, and commercial endeavors. Komodo’s data-driven intelligence is expected to be a critical tool as we work towards commercialization and delivering transformative therapies to patients.”